Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Authors
Keywords
-
Journal
BMC Pulmonary Medicine
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-03
DOI
10.1186/s12890-020-01248-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mepolizumab effectiveness and identification of super-responders in severe asthma
- (2020) Erin S. Harvey et al. EUROPEAN RESPIRATORY JOURNAL
- Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
- (2020) Richard P. Ramonell et al. LUNG
- A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan
- (2019) Hiromasa Inoue et al. npj Primary Care Respiratory Medicine
- Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD
- (2019) Masami Taniguchi et al. ALLERGOLOGY INTERNATIONAL
- Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
- (2019) Barak Pertzov et al. JOURNAL OF ASTHMA
- Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
- (2019) Takanori Numata et al. BMC Pulmonary Medicine
- Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
- (2018) Ken Ohta et al. ALLERGOLOGY INTERNATIONAL
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
- (2018) J Mark FitzGerald et al. Lancet Respiratory Medicine
- A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease
- (2018) Katherine L. Tuttle et al. Journal of Allergy and Clinical Immunology-In Practice
- Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab
- (2018) Lawrence DuBuske et al. ALLERGY AND ASTHMA PROCEEDINGS
- Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma
- (2018) Eugene R. Bleecker et al. EUROPEAN RESPIRATORY JOURNAL
- Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
- (2018) William Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review
- (2018) Arnaud Bourdin et al. EUROPEAN RESPIRATORY JOURNAL
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to omalizumab in patients with severe allergic asthma: A real-life study
- (2017) Louise Zierau et al. RESPIRATORY MEDICINE
- Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
- (2017) Terufumi Shimoda et al. ALLERGOLOGY INTERNATIONAL
- Japanese guidelines for adult asthma 2017
- (2017) Masakazu Ichinose et al. ALLERGOLOGY INTERNATIONAL
- Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease
- (2017) Whitney W. Stevens et al. Journal of Allergy and Clinical Immunology-In Practice
- Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
- (2016) A. Magnan et al. ALLERGY
- Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F 2 overproduction in aspirin-exacerbated respiratory disease
- (2016) Hiroaki Hayashi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity
- (2015) D. R. Morales et al. ALLERGY
- Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease
- (2015) Whitney W. Stevens et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The prevalence of severe refractory asthma
- (2015) Pieter-Paul W. Hekking et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Asthma outcomes: Pulmonary physiology
- (2012) Robert S. Tepper et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The minimally important difference of the Asthma Control Test
- (2009) Michael Schatz et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More